Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PanGenomic Health, Inc. Class A ( (TSE:NARA) ) just unveiled an announcement.
PanGenomic Health Inc. has provided an update regarding the management cease trade order (MCTO) issued by the British Columbia Securities Commission due to delays in filing its audited annual financial statements for 2024. The company expects to complete the necessary filings by June 30, 2025, and the MCTO restricts trading by the CEO and CFO until the filings are made. This situation does not affect shareholder trading, and the company will continue to issue bi-weekly updates until the matter is resolved.
Spark’s Take on TSE:NARA Stock
According to Spark, TipRanks’ AI Analyst, TSE:NARA is a Underperform.
The overall stock score is driven by severe financial instability, with no revenue generation and increasing net losses. Technical analysis provides a mixed picture, suggesting potential short-term recovery but still reflecting overall negative momentum. The negative P/E ratio and lack of dividend yield further decrease the stock’s attractiveness.
To see Spark’s full report on TSE:NARA stock, click here.
More about PanGenomic Health, Inc. Class A
PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The company’s initial focus is on supporting mental health, and it aims to promote and improve health and wellness by providing technology that identifies plant-based solutions tailored to individual health profiles.
Average Trading Volume: 13,061
Technical Sentiment Signal: Buy
Current Market Cap: C$4.99M
For an in-depth examination of NARA stock, go to TipRanks’ Overview page.